When ECT Doesn’t Work: Next Steps for Treatment-Resistant Depression

By Joao L. de Quevedo, MD, PhD, Executive Director, Center for Interventional Psychiatry UTHealth Houston
July 21, 2025

Electroconvulsive therapy (ECT) remains one of the most effective interventions for treatment-resistant depression (TRD), with response rates often exceeding 70%. For many patients who have not found relief through psychotherapy or multiple medication trials, ECT can offer life-changing improvement. However, a significant minority of patients—estimated at 20–30%—do not respond adequately. For clinicians, patients, and families, this reality can be discouraging, but it should not mark the end of the therapeutic journey.

In this post, I’ll outline a clinical framework for managing patients with TRD who do not respond to ECT, including reevaluation, alternative somatic treatments, novel pharmacological strategies, and ongoing psychosocial support.

  1. Reassess the Diagnosis and Contributing Factors

Before moving to new interventions, it is essential to revisit the diagnostic formulation:

  • Is the diagnosis accurate? Consider bipolar depression, borderline personality disorder, schizoaffective disorder, or undetected neurodegenerative conditions, which may alter treatment response.
  • Are there comorbidities interfering with treatment? Substance use, anxiety, PTSD, chronic pain, or cognitive disorders may blunt the ECT response.
  • Is adherence and treatment delivery optimal? Review whether the full ECT course was completed, if adequate seizure thresholds were achieved, and whether right unilateral, bifrontal, or bitemporal placements were used effectively.
  1. Consider Other Somatic Treatments

If ECT fails, several evidence-based neuromodulation options may still offer benefit:

  • Ketamine or esketamine: Intravenous racemic ketamine or intranasal esketamine has rapid-acting antidepressant properties and may be effective even in ECT non-responders.
  • Repetitive transcranial magnetic stimulation (rTMS): Especially accelerated or deep TMS protocols may help, although less robust than ECT.
  • Vagus nerve stimulation (VNS): Approved for TRD with long-term benefit in some patients, though the onset of effect is slow.
  • Deep brain stimulation (DBS): Still investigational for depression but may be considered in research settings.
  • Transcranial direct current stimulation (tDCS) and focused ultrasound: Experimental, but emerging as potential alternatives.
  1. Optimize Pharmacologic Strategies

Medication may still play a critical role, especially in combinations or augmentation strategies:

  • Augmentation with lithium, thyroid hormone (T3), or atypical antipsychotics.
  • MAOIs (e.g., tranylcypromine): Often underutilized and potentially very effective in classic melancholic or atypical depression.
  • Re-challenging past partial responders: With a different strategy or support system in place.
  • Psychostimulants (e.g., methylphenidate, modafinil): As adjuncts for energy and anhedonia.
  1. Psychotherapy and Functional Recovery

While biological treatments are central in TRD, psychotherapy remains essential:

  • Cognitive Behavioral Therapy (CBT) tailored for residual symptoms.
  • Acceptance and Commitment Therapy (ACT) or Dialectical Behavior Therapy (DBT) for patients with comorbid personality pathology or suicidality.
  • Functional rehabilitation programs that address social withdrawal, occupational function, and self-efficacy.
  1. Enroll in a Clinical Trial

Many patients who do not respond to ECT qualify for research protocols investigating cutting-edge treatments. Academic medical centers often host trials exploring psychedelic-assisted therapy, novel pharmacologic agents, or precision neuromodulation.

  1. Support, Patience, and Persistence

Finally, TRD is often a chronic and relapsing condition. Setbacks are expected. The therapeutic alliance, ongoing family involvement, and a multidisciplinary approach are critical. The message for patients is clear: even when ECT doesn’t work, there are still pathways forward.

Primary Reference

  1. McIntyre RS, Alsuwaidan M, Baune BT, Berk M, Demyttenaere K, Goldberg JF, et al. Treatment-resistant depression: definition, prevalence, detection, management, and investigational interventions. World Psychiatry. 2023 Oct;22(3):394-412. doi: 10.1002/wps.21120. PMID: 37713549; PMCID: PMC10503923. https://pubmed.ncbi.nlm.nih.gov/37713549/  (external link)

Selected References

1. Rush AJ, Aaronson ST, Demyttenaere K. Difficult-to-treat depression: a clinical and research roadmap for when remission is elusive. Lancet. 2019;394(10201):1565–1579.
2. McAllister-Williams RH, Arango C, Blier P, et al. The identification, assessment and management of difficult-to-treat depression: an international consensus statement. Journal of Affective Disorders. 2020;267:264–282.
3. McIntyre RS, Rosenblat JD, Nemeroff CB, et al. Synthesizing the evidence for ketamine and esketamine in treatment-resistant depression: an international expert opinion on the available evidence and implementation. American Journal of Psychiatry. 2021;178(5):383–399.
4. Kellner CH, Obbels J, Sienaert P. When to consider electroconvulsive therapy. Acta Psychiatrica Scandinavica. 2020;141(4):304–315.

Contact

Request for Second Opinion Form – https://Go.uth.edu/CIPIntake (external link).

Phone – (713) 486-2621

Fax – (713) 500-2728

E-mail – [email protected]